[Bortezomib, rituximab combined with chemotherapy for mantle cell lymphoma: two cases report and literature review].
作者信息
Su J, Xu H, Shi X, Sui X F, Cui Z G, Zhao H G
机构信息
Department of Hematology, the Affiliated Hospital of Qingdao University, Qingdao 266003, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2016 Dec 14;37(12):1080-1081. doi: 10.3760/cma.j.issn.0253-2727.2016.12.014.
Abstract
摘要
相似文献
1
[Bortezomib, rituximab combined with chemotherapy for mantle cell lymphoma: two cases report and literature review].硼替佐米、利妥昔单抗联合化疗治疗套细胞淋巴瘤：两例报告及文献综述
Zhonghua Xue Ye Xue Za Zhi. 2016 Dec 14;37(12):1080-1081. doi: 10.3760/cma.j.issn.0253-2727.2016.12.014.
2
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.硼替佐米联合利妥昔单抗和超分割环磷酰胺、长春新碱、多柔比星和地塞米松方案交替硼替佐米、利妥昔单抗、甲氨蝶呤和阿糖胞苷治疗初治套细胞淋巴瘤的 2 期临床试验。
Cancer. 2018 Jun 15;124(12):2561-2569. doi: 10.1002/cncr.31361. Epub 2018 May 3.
3
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.不适合移植的新诊断套细胞淋巴瘤患者中硼替佐米、利妥昔单抗、环磷酰胺、多柔比星、泼尼松（VR-CAP）与利妥昔单抗、环磷酰胺、多柔比星、长春新碱、泼尼松（R-CHOP）的比较：一项随机、开放标签、3 期研究的最终总生存结果。
Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19.
4
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.硼替佐米和利妥昔单抗维持联合治疗巩固自体造血干细胞移植后套细胞淋巴瘤患者的多中心 II 期试验。
J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3.
5
Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab.
J Chemother. 2016 Oct;28(5):435-40. doi: 10.1080/1120009X.2016.1181293. Epub 2016 Jun 28.
6
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.一项利妥昔单抗、苯达莫司汀、硼替佐米和地塞米松用于一线治疗老年套细胞淋巴瘤患者的 2 期研究。
Haematologica. 2019 Jan;104(1):138-146. doi: 10.3324/haematol.2018.191429. Epub 2018 Aug 31.
7
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.硼替佐米联合利妥昔单抗-HyperCVAD 方案交替利妥昔单抗、甲氨蝶呤和阿糖胞苷治疗未经治疗的侵袭性套细胞淋巴瘤的 I 期临床试验。
Br J Haematol. 2010 Oct;151(1):47-53. doi: 10.1111/j.1365-2141.2010.08315.x. Epub 2010 Aug 5.
8
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.来那度胺、硼替佐米、多柔比星、地塞米松和苯丁酸氮芥（RiPAD+C）联合方案作为老年套细胞淋巴瘤患者一线治疗：GOELAMS Ⅱ期试验结果。
Ann Oncol. 2012 Jun;23(6):1555-61. doi: 10.1093/annonc/mdr450. Epub 2011 Oct 19.
9
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.在随机3期LYM-3002研究中，一线利妥昔单抗、环磷酰胺、阿霉素和泼尼松联合硼替佐米（VR-CAP）或长春新碱（R-CHOP）对一部分新诊断的符合移植医学标准的套细胞淋巴瘤患者的疗效和安全性。
Leuk Lymphoma. 2018 Apr;59(4):896-903. doi: 10.1080/10428194.2017.1365855. Epub 2018 Jan 17.
10
Diffuse aggressive lymphoma.弥漫性大B细胞淋巴瘤
Hematology Am Soc Hematol Educ Program. 2004:221-36. doi: 10.1182/asheducation-2004.1.221.
本文引用的文献
1
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.R-CHOP方案联合硼替佐米诱导治疗继以硼替佐米维持治疗初诊套细胞淋巴瘤的II期试验：SWOG S0601
Br J Haematol. 2016 Jan;172(2):208-18. doi: 10.1111/bjh.13818. Epub 2015 Oct 22.
2
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.硼替佐米为基础的治疗新诊断的套细胞淋巴瘤。
N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096.
3
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.硼替佐米联合 CHOP-利妥昔单抗方案治疗初治弥漫性大 B 细胞淋巴瘤和套细胞淋巴瘤。
J Clin Oncol. 2011 Feb 20;29(6):690-7. doi: 10.1200/JCO.2010.31.1142. Epub 2010 Dec 28.
4
Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.硼替佐米和利妥昔单抗联合治疗通过影响多条生存和死亡通路促进套细胞淋巴瘤细胞凋亡。
MAbs. 2009 Jan-Feb;1(1):31-40. doi: 10.4161/mabs.1.1.7472.
5
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).利妥昔单抗联合环磷酰胺、阿霉素、长春新碱及泼尼松进行免疫化疗可显著提高反应率并延长至治疗失败时间，但对既往未治疗的套细胞淋巴瘤患者的长期预后无改善：德国低度淋巴瘤研究组（GLSG）一项前瞻性随机试验的结果
J Clin Oncol. 2005 Mar 20;23(9):1984-92. doi: 10.1200/JCO.2005.08.133. Epub 2005 Jan 24.
Zotero 插件